SE8004002L
(sv)
*
|
1980-05-29 |
1981-11-30 |
Arvidsson Folke Lars Erik |
Terapeutiskt anvendbara tetralinderivat
|
US4839104A
(en)
*
|
1987-06-11 |
1989-06-13 |
Pfizer, Inc. |
Process for preparing sertraline intermediates
|
US4777288A
(en)
*
|
1987-06-11 |
1988-10-11 |
Pfizer Inc. |
Process for preparing a 4,4-diphenylbutanoic acid derivative
|
FR2623802B1
(fr)
*
|
1987-11-26 |
1990-05-04 |
Lucien Laboratoires |
Derives d'amino-4 trifluoromethyl-1 tetralines. leur preparation et leur application en therapeutique
|
US4855500A
(en)
*
|
1988-05-04 |
1989-08-08 |
Pfizer Inc. |
Process for preparing a ketimine
|
FR2632633B1
(fr)
*
|
1988-06-08 |
1991-04-05 |
Delalande Sa |
Procede de preparation de 4-aryl-1-tetralones
|
US4981870A
(en)
*
|
1989-03-07 |
1991-01-01 |
Pfizer Inc. |
Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
|
US5130338A
(en)
*
|
1989-08-30 |
1992-07-14 |
Pfizer Inc. |
Method of treating chemical dependencies using sertraline
|
DK0415612T3
(da)
*
|
1989-08-30 |
1993-12-13 |
Pfizer |
Anvendelse af sertralin til behandling af afhængigheder af kemiske stoffer
|
US4940731A
(en)
*
|
1989-08-30 |
1990-07-10 |
Pfizer Inc. |
Method of treating premature ejaculation using sertraline
|
US4962128A
(en)
*
|
1989-11-02 |
1990-10-09 |
Pfizer Inc. |
Method of treating anxiety-related disorders using sertraline
|
FR2665443B1
(fr)
*
|
1990-08-03 |
1992-11-06 |
Lucien Laboratoires |
Derives d'amino-4-methyl-1-tetralines, leur preparation et leur application en therapeutique.
|
US5082970A
(en)
*
|
1991-03-06 |
1992-01-21 |
Pfizer Inc. |
Process for recycling amine isomer
|
GB9114948D0
(en)
*
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
GB9114947D0
(en)
*
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline
|
US5196607A
(en)
*
|
1992-02-14 |
1993-03-23 |
Pfizer Inc. |
Process for preparing ketone enantiomer
|
US5248699A
(en)
*
|
1992-08-13 |
1993-09-28 |
Pfizer Inc. |
Sertraline polymorph
|
US5288916A
(en)
*
|
1993-03-25 |
1994-02-22 |
Bend Research, Inc. |
Enantiomeric resolution of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone
|
CA2176500C
(fr)
*
|
1993-11-30 |
1999-09-28 |
George J. Quallich |
Procede de preparation d'une tetralone chirale
|
US5597826A
(en)
|
1994-09-14 |
1997-01-28 |
Pfizer Inc. |
Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
|
US6410794B1
(en)
|
1994-12-16 |
2002-06-25 |
Uop Llc |
Process for preparation of pharmaceutically desired chiral tetralone from tetralones
|
US6455736B1
(en)
|
1994-12-16 |
2002-09-24 |
Uop Llc |
Process for preparation of pharmaceutically desired sertraline and sertraline analogs
|
AU5966196A
(en)
*
|
1995-06-08 |
1997-01-09 |
Eli Lilly And Company |
Methods of treating cold and allergic rhinitis
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
DK0759299T3
(da)
*
|
1995-08-16 |
2000-08-07 |
Lilly Co Eli |
Potensering af serotoninrespons
|
US5734083A
(en)
*
|
1996-05-17 |
1998-03-31 |
Torcan Chemical Ltd. |
Sertraline polymorph
|
HU222341B1
(hu)
*
|
1996-12-18 |
2003-06-28 |
Richter Gedeon Vegyészeti Gyár Rt. |
Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
|
TW403740B
(en)
*
|
1997-06-10 |
2000-09-01 |
Novartis Ag |
Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
|
US20040208926A1
(en)
*
|
1997-07-01 |
2004-10-21 |
Pfizer Inc |
Solubilized sertraline compositions
|
US20030133974A1
(en)
*
|
1997-07-01 |
2003-07-17 |
Curatolo William John |
Encapsulated solution dosage forms of sertraline
|
AU739261B2
(en)
*
|
1997-07-01 |
2001-10-11 |
Pfizer Inc. |
Sertraline salts and sustained-release dosage forms of sertraline
|
EP0928784B1
(fr)
*
|
1997-12-11 |
2002-06-12 |
TORCAN CHEMICAL Ltd |
Sertraline polymorphe ayant une hydrosolubilité améliorée
|
IN191358B
(fr)
|
1998-01-16 |
2003-11-29 |
Pfizer Prod Inc |
|
WO1999046233A1
(fr)
*
|
1998-03-09 |
1999-09-16 |
Sumika Fine Chemicals Co., Ltd. |
Derives de l'alcool benzylique
|
AU759530B2
(en)
*
|
1998-03-18 |
2003-04-17 |
Ciba Specialty Chemicals Holding Inc. |
Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
|
FR2777000B1
(fr)
|
1998-04-01 |
2002-09-27 |
Catalys |
Procede de preparation de la sertraline racemique
|
PT957099E
(pt)
|
1998-04-15 |
2003-02-28 |
Pfizer Prod Inc |
Carboxamidas heterociclicas
|
US6054614A
(en)
*
|
1998-04-23 |
2000-04-25 |
Ciba Specialty Chemicals Corporation |
Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds
|
HU226424B1
(en)
*
|
1998-05-05 |
2008-12-29 |
Egis Gyogyszergyar Nyrt |
Process for producing enantiomer mixture for preparation of sertraline
|
HU226423B1
(en)
*
|
1998-05-05 |
2008-12-29 |
Egis Gyogyszergyar Nyrt |
Process for producing a 1(2h)-naphtalene-1-ylidene derivative
|
IN182588B
(fr)
*
|
1998-05-12 |
1999-05-08 |
Sun Pharmaceutical Ind Ltd |
|
DE19830201A1
(de)
*
|
1998-07-07 |
2000-01-13 |
Boehringer Ingelheim Pharma |
Mittel mit antidepressiver Wirkung
|
US6727283B2
(en)
|
1998-10-13 |
2004-04-27 |
Pfizer Inc. |
Sertraline oral concentrate
|
HUP0104470A3
(en)
*
|
1998-10-13 |
2003-12-29 |
Pfizer Prod Inc |
Sertraline oral concentrate and process for its preparation
|
IL132500A0
(en)
|
1998-10-29 |
2001-03-19 |
Pfizer Prod Inc |
Stereoselective microbial reduction of a racemic tetralone
|
WO2000025598A1
(fr)
*
|
1998-11-03 |
2000-05-11 |
Dandy A/S |
Esters d'acide gras de saccharose prevus pour augmenter la liberation d'ingredients actifs
|
US6518284B2
(en)
*
|
1998-11-18 |
2003-02-11 |
Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. |
4-substituted piperidines
|
JP2002531427A
(ja)
*
|
1998-11-27 |
2002-09-24 |
テバ ファーマシューティカル インダストリーズ リミティド |
セルトラリン塩酸塩多形体
|
US6500987B1
(en)
|
1998-11-27 |
2002-12-31 |
Teva Pharmaceutical Industries Ltd. |
Sertraline hydrochloride polymorphs
|
EP1630156A1
(fr)
*
|
1998-11-27 |
2006-03-01 |
Teva Pharmaceutical Industries Ltd |
Polymorphes de chlorhydrate de Sertraline
|
JP2002538134A
(ja)
*
|
1999-03-01 |
2002-11-12 |
ファイザー・インク |
療法に有用な1,2,3,4−テトラヒドロ−1−ナフタレンアミン化合物
|
US6245782B1
(en)
|
1999-05-17 |
2001-06-12 |
Heartdrug Research L.L.C. |
Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
|
US6593496B1
(en)
|
1999-06-09 |
2003-07-15 |
Pfizer Inc |
Process for preparing sertraline from chiral tetralone
|
DK1200387T3
(da)
*
|
1999-07-29 |
2004-07-19 |
Ciba Sc Holding Ag |
Fremgangsmåde til den cis-selektive katalytiske hydrogenering af cyclohexylidenaminer
|
US6495721B1
(en)
*
|
1999-08-09 |
2002-12-17 |
Teva Pharmaceutical Industries Ltd. |
Sertraline hydrochloride Form II and methods for the preparation thereof
|
IN185109B
(fr)
*
|
1999-09-01 |
2000-11-18 |
Torrent Pharmaceuticals Ltd |
|
DK174219B1
(da)
*
|
1999-10-27 |
2002-09-30 |
Gea Farmaceutisk Fabrik As |
Forbedret syntese af racemisk sertralin
|
US7442838B2
(en)
*
|
1999-10-29 |
2008-10-28 |
Ciba Specialty Chemicals Corp. |
Polymorphic forms of sertraline hydrochloride
|
US20050119351A1
(en)
*
|
1999-10-29 |
2005-06-02 |
Van Der Schaaf Paul A. |
Polymorphic forms of sertraline hydrochloride
|
TWI260315B
(en)
|
1999-10-29 |
2006-08-21 |
Ciba Sc Holding Ag |
Polymorphic forms of sertraline hydrochloride
|
ES2245652T3
(es)
|
1999-11-16 |
2006-01-16 |
Ciba Specialty Chemicals Holding Inc. |
Procedimiento para la preparacion de cetiminas.
|
CA2388814A1
(fr)
|
1999-11-16 |
2001-05-25 |
Ciba Specialty Chemicals Holding Inc. |
Procede de preparation de cetimines
|
US6380200B1
(en)
|
1999-12-07 |
2002-04-30 |
Pfizer, Inc. |
Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
|
IL150332A0
(en)
*
|
1999-12-21 |
2002-12-01 |
Teva Pharma |
Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
|
AU1724301A
(en)
|
1999-12-23 |
2001-07-09 |
Pfizer Products Inc. |
Hydrogel-driven layered drug dosage form
|
IN187170B
(fr)
|
2000-01-04 |
2002-02-23 |
Sun Pharmaceutical Ind Ltd |
|
KR100704590B1
(ko)
*
|
2000-03-14 |
2007-04-10 |
테바 파마슈티컬 인더스트리즈 리미티드 |
(+)-시스-세르트랄린의 신규한 제조 방법
|
AU5702201A
(en)
*
|
2000-04-13 |
2001-10-30 |
Mayo Foundation |
Abeta<sub>42</sub> lowering agents
|
IN192343B
(fr)
*
|
2000-05-26 |
2004-04-10 |
Ranbaxy Lab Ltd |
|
DE60119047D1
(de)
*
|
2000-08-31 |
2006-06-01 |
Pfizer |
Phenoxyphenylheterozyklen als Serotonin-Wiederaufnahmehemmer
|
US6630504B2
(en)
|
2000-08-31 |
2003-10-07 |
Pfizer Inc. |
Phenoxyphenylheterocyclyl derivatives as SSRIs
|
US6482440B2
(en)
|
2000-09-21 |
2002-11-19 |
Phase 2 Discovery, Inc. |
Long acting antidepressant microparticles
|
US6645946B1
(en)
|
2001-03-27 |
2003-11-11 |
Pro-Pharmaceuticals, Inc. |
Delivery of a therapeutic agent in a formulation for reduced toxicity
|
EP1397343A1
(fr)
*
|
2001-05-31 |
2004-03-17 |
Orion Corporation Fermion |
Procede de fabrication de chlorhydrate de sertraline polymorphe de forme ii
|
WO2002102761A1
(fr)
*
|
2001-06-15 |
2002-12-27 |
Orion Corporation Fermion |
Nouveau procede pour la preparation de (is-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphtalenamine
|
US6723878B2
(en)
|
2001-06-15 |
2004-04-20 |
Orion Corporation Fermion |
Method for preparing sertraline
|
CA2462903C
(fr)
*
|
2001-10-12 |
2011-09-20 |
Serenix Pharmaceuticals, Llc |
Antagonistes v1a de vasopressine beta-lactamyl
|
JP4625637B2
(ja)
|
2002-02-22 |
2011-02-02 |
シャイア エルエルシー |
活性物質送達系及び活性物質を保護し投与する方法
|
WO2003093217A1
(fr)
*
|
2002-04-29 |
2003-11-13 |
Teva Pharmaceutical Industries Ltd. |
Procedes pour preparer une forme ii polymorphe d'hydrochlorure de sertraline, preparations pharmaceutiques et procedes d'administration
|
AU2003254475A1
(en)
*
|
2002-07-29 |
2004-02-16 |
Cipla Limited |
Sertraline
|
RU2310647C2
(ru)
*
|
2002-11-07 |
2007-11-20 |
Торрент Фармасьютикалз Лтд |
Способ получения полиморфной формы гидрохлорида сертралина
|
US20040131672A1
(en)
*
|
2003-01-07 |
2004-07-08 |
Nilobon Podhipleux |
Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
|
EP1603548A4
(fr)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
Composition et methode de traitement de troubles neurodegeneratifs
|
WO2004087732A2
(fr)
*
|
2003-03-11 |
2004-10-14 |
Sun Pharmaceutical Industries Limited |
Procede de preparation de (1s, 4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphtylamine
|
US7276629B2
(en)
*
|
2003-04-14 |
2007-10-02 |
Teva Pharmaceutical Industries Ltd. |
Hydrogenation of imine intermediates of sertraline with catalysts
|
WO2005000786A1
(fr)
*
|
2003-05-23 |
2005-01-06 |
Transform Pharmaceuticals, Inc. |
Compositions de sertraline
|
US20050070577A1
(en)
*
|
2003-07-03 |
2005-03-31 |
Pfizer Inc. |
Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
|
AU2004311577A1
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
EP1648854A1
(fr)
*
|
2003-07-15 |
2006-04-26 |
RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. |
Procedes de preparation de polymorphes de chlorhydrate de sertraline
|
US7173153B2
(en)
*
|
2003-07-15 |
2007-02-06 |
Recordati Industria Chimica E. Farmaceutica S.P.A. |
Sertraline hydrochloride form II and methods for the preparation thereof
|
HU227495B1
(en)
*
|
2003-07-21 |
2011-07-28 |
Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag |
Process for producing of imine intermediate
|
EP1660432A2
(fr)
*
|
2003-09-05 |
2006-05-31 |
Teva Pharmaceutical Industries Limited |
Procede de recyclage pour l'elaboration de sertraline
|
CA2538412A1
(fr)
*
|
2003-09-12 |
2005-03-24 |
Warner-Lambert Company Llc |
Combinaison comportant un ligand alpha-2-delta et un inhibiteur selectif du recaptage de la serotonine et/ou un inhibiteur selectif du recaptage de la noradrenaline et permettant le traitement de la depression et des troubles anxieux
|
NZ545494A
(en)
|
2003-09-12 |
2009-10-30 |
Pfizer |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
JP5069907B2
(ja)
*
|
2003-09-17 |
2012-11-07 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
縮合複素環式化合物
|
AU2004289512A1
(en)
*
|
2003-11-04 |
2005-05-26 |
Cipla Limited |
Process for the preparation of polymorphs of selective serotonin reuptake inhibitor
|
US7671072B2
(en)
*
|
2003-11-26 |
2010-03-02 |
Pfizer Inc. |
Aminopyrazole derivatives as GSK-3 inhibitors
|
US20050250803A1
(en)
*
|
2003-11-26 |
2005-11-10 |
Pfizer Inc |
Combination of dopamine agonists and monoamine reuptake inhibitors
|
AU2004305563C1
(en)
|
2003-12-11 |
2011-07-07 |
Sunovion Pharmaceuticals Inc. |
Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
|
US20070293538A1
(en)
*
|
2004-04-13 |
2007-12-20 |
Myriad Genetics, Incorporated |
Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
|
CA2567249A1
(fr)
*
|
2004-04-19 |
2006-10-05 |
Jds Pharmaceuticals, Llc |
Combinaisons de lithium et utilisations associees
|
BRPI0509592A
(pt)
*
|
2004-05-06 |
2007-09-25 |
Cydex Inc |
formulações de sabor mascarado, contendo sertralina e ciclodextrina de éter de sulfoalquila
|
PE20060437A1
(es)
|
2004-06-18 |
2006-06-08 |
Novartis Ag |
COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
|
GB0415746D0
(en)
|
2004-07-14 |
2004-08-18 |
Novartis Ag |
Organic compounds
|
WO2006020853A2
(fr)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
|
WO2006020852A2
(fr)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
|
WO2006020850A2
(fr)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
|
US7345201B2
(en)
*
|
2005-02-23 |
2008-03-18 |
Teva Pharmaceutical Industries, Ltd. |
Processes for preparing sertraline
|
WO2006102283A2
(fr)
|
2005-03-22 |
2006-09-28 |
Azevan Pharmaceuticals, Inc. |
Acides beta-lactamylalcanoiques destines au traitement des troubles premenstruels
|
JP2006265169A
(ja)
*
|
2005-03-24 |
2006-10-05 |
Tokuyama Corp |
アルキリデンコハク酸化合物の製造方法
|
GB0507090D0
(en)
*
|
2005-04-07 |
2005-05-11 |
Sandoz Ag |
Process for preparing polymorphic form ll of sertraline hydrochloride
|
GB0507298D0
(en)
|
2005-04-11 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
GT200600164A
(es)
|
2005-04-22 |
2007-03-14 |
|
Derivados de dihidrobenzofuranos y usos de los mismos
|
GT200600158A
(es)
*
|
2005-04-22 |
2006-11-28 |
|
Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina
|
CA2605587A1
(fr)
*
|
2005-04-22 |
2006-11-02 |
Wyeth |
Derives de chromane et de chromene, et leurs utilisations
|
CA2604759A1
(fr)
*
|
2005-04-22 |
2006-11-02 |
Wyeth |
Derives de dihydrobenzofurane et utilisations de ceux-ci
|
CN101203218A
(zh)
*
|
2005-04-22 |
2008-06-18 |
惠氏公司 |
苯并呋喃基链烷胺衍生物和其作为5-ht2c激动剂的用途
|
WO2006129324A2
(fr)
*
|
2005-06-03 |
2006-12-07 |
Hetero Drugs Limited |
Synthese hautement stereoselective de sertraline
|
US20070100165A1
(en)
*
|
2005-06-09 |
2007-05-03 |
Ronen Borochovitz |
Process for preparation of sertraline hydrochloride form I
|
EP1896002A4
(fr)
*
|
2005-06-27 |
2009-11-25 |
Biovail Lab Int Srl |
Formulations a liberation modifiee d'un sel de bupropion
|
EP2317316A3
(fr)
|
2005-07-08 |
2011-06-15 |
Braincells, Inc. |
Procédés permettant d'identifier l'agent et les conditions qui modulent la neurogénèse
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
CN101268068B
(zh)
*
|
2005-07-19 |
2015-12-02 |
阿泽范药品公司 |
β-内酰胺基苯丙氨酸、半胱氨酸和丝氨酸血管加压素拮抗剂
|
US7598255B2
(en)
*
|
2005-08-04 |
2009-10-06 |
Janssen Pharmaceutica Nv |
Pyrimidine compounds as serotonin receptor modulators
|
EP1940389A2
(fr)
|
2005-10-21 |
2008-07-09 |
Braincells, Inc. |
Modulation de la neurogenese par inhibition de la pde
|
CA2625210A1
(fr)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
|
GB0525673D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
GB0525672D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
ES2566479T3
(es)
*
|
2006-01-06 |
2016-04-13 |
Sunovion Pharmaceuticals Inc. |
Inhibidores de reabsorción de monoamina con base en tetralona
|
US20070213562A1
(en)
*
|
2006-01-23 |
2007-09-13 |
Ami Zoran |
Recycling process for preparing sertraline
|
FR2912057B1
(fr)
*
|
2007-02-07 |
2009-04-17 |
Sanofi Aventis Sa |
Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
PA8720801A1
(es)
*
|
2006-03-24 |
2008-11-19 |
Wyeth Corp |
Nuevas combinaciones terapeuticas para el tratamiento de la depresion
|
WO2007119247A2
(fr)
*
|
2006-04-17 |
2007-10-25 |
Unichem Laboratories Limited |
Procédé de production amélioré destiné à la préparation de la forme polymorphe ii de l'hydrochlorure de cis-(1s)-n-methyl-4-(3,4-dichlorophényle)-1,2,3,4-tétrahydro-1-napthlèneamine (hydrochlorure de sertraline)
|
TR200808115T1
(tr)
*
|
2006-04-28 |
2009-03-23 |
Sandoz Ag |
4(S,R)-(3,4-diklorofenil)-3,4-dihidro-l(2H)-naftalin-l-ilid n]metilamin'ın Hazırlanması için Proses.@
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
MX2008014320A
(es)
|
2006-05-09 |
2009-03-25 |
Braincells Inc |
Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US7518019B2
(en)
|
2006-06-01 |
2009-04-14 |
Hetero Drugs Limited |
Processes for preparing sertraline hydrochloride crystalline forms
|
WO2007146796A2
(fr)
*
|
2006-06-13 |
2007-12-21 |
Ramot At Tel-Aviv University Ltd. |
Composés antiprolifératifs, compositions contenant ceux-ci et procédés d'utilisation de ceux-ci
|
US7893053B2
(en)
*
|
2006-06-16 |
2011-02-22 |
Theracos, Inc. |
Treating psychological conditions using muscarinic receptor M1 antagonists
|
EP2046119A2
(fr)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Traitement de troubles psychiatriques
|
TW200817003A
(en)
*
|
2006-07-31 |
2008-04-16 |
Sanofi Aventis |
Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
|
US20060257475A1
(en)
*
|
2006-08-17 |
2006-11-16 |
Boehringer Ingelheim International Gmbh |
Stable Sertraline Hydrochloride Formulation and Method
|
MX2009002496A
(es)
|
2006-09-08 |
2009-07-10 |
Braincells Inc |
Combinaciones que contienen un derivado de 4-acilaminopiridina.
|
US20100016274A1
(en)
*
|
2006-09-14 |
2010-01-21 |
Koppel Gary A |
Beta-lactam cannabinoid receptor modulators
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
FR2909376A1
(fr)
*
|
2006-11-30 |
2008-06-06 |
Cerep Sa |
Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
|
WO2008083204A2
(fr)
*
|
2006-12-28 |
2008-07-10 |
Braincells, Inc. |
Modulation de la neurogenèse par des ligands mélatoninergiques
|
EP2125017A2
(fr)
*
|
2007-01-11 |
2009-12-02 |
Braincells, Inc. |
Modulation de la neurogenèse en utilisant du modafinil
|
CA2594198A1
(fr)
*
|
2007-07-20 |
2009-01-20 |
Apotex Pharmachem Inc. |
Procede inedit de preparation d'hydrochlorure de sertraline de forme ii
|
US20090062399A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched sertraline
|
WO2009128058A1
(fr)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Produits psycho-pharmaceutiques
|
WO2009128057A2
(fr)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Produits psycho-pharmaceutiques
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
US9260413B2
(en)
*
|
2010-03-04 |
2016-02-16 |
Merck Sharp & Dohme Corp. |
Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
|
EP2380595A1
(fr)
|
2010-04-19 |
2011-10-26 |
Nlife Therapeutics S.L. |
Compositions et procédés pour la fourniture sélective de molécules d'oligonucléotides à des types de neurones spécifiques
|
US8440655B2
(en)
|
2010-06-21 |
2013-05-14 |
Theracos, Inc. |
Combination therapy for the treatment of diabetes
|
PL2587919T3
(pl)
|
2010-07-01 |
2018-05-30 |
Azevan Pharmaceuticals, Inc. |
Sposoby leczenia zespołu stresu pourazowego
|
US20140010883A1
(en)
|
2011-03-17 |
2014-01-09 |
Lupin Limited |
Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
|
KR101340270B1
(ko)
*
|
2011-11-10 |
2013-12-10 |
보령제약 주식회사 |
(+)-시스-서트랄린의 선택적인 제조방법
|
CA2879489A1
(fr)
*
|
2012-10-18 |
2014-04-24 |
F.Hoffmann-La Roche Ag |
Derives d'ethynyl utilises en tant que modulateurs de l'activite des recepteurs mglur5
|
PL3122743T3
(pl)
|
2014-03-28 |
2023-05-02 |
Azevan Pharmaceuticals, Inc. |
Kompozycje i sposoby leczenia chorób neurodegeneracyjnych
|
US10266481B2
(en)
|
2014-06-20 |
2019-04-23 |
Council Of Scientific & Industrial Research |
Organocatalytic asymmetric synthesis of antidepressants
|
EP3180337B1
(fr)
*
|
2014-08-11 |
2018-10-10 |
Hydra Biosciences, Inc. |
Dérivés de pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione
|
WO2016023830A1
(fr)
*
|
2014-08-11 |
2016-02-18 |
Hydra Biosciences, Inc. |
Dérivés de pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione
|
EP3180342B1
(fr)
*
|
2014-08-11 |
2019-06-26 |
Hydra Biosciences, Inc. |
Dérivés de pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione
|
EP3180345B1
(fr)
*
|
2014-08-11 |
2018-10-10 |
Hydra Biosciences, Inc. |
Dérivés thieno- et furo[2,3-d]pyrimidine-2,4[1h,3h]-dione en tant que modulateurs trpc5 pour le traitement de maladies neuropsychiatriques
|
US10138110B2
(en)
|
2015-09-21 |
2018-11-27 |
S. C. Johnson & Son, Inc. |
Attachment and system for mixing and dispensing a chemical and diluent
|
TW201919625A
(zh)
|
2017-09-15 |
2019-06-01 |
美商愛治凡製藥公司 |
用於治療腦損傷之組合物及方法
|
WO2020043716A1
(fr)
|
2018-08-27 |
2020-03-05 |
Katholieke Universiteit Leuven |
Ciblage pharmacologique de la synthèse de novo de sérine/glycine
|